Patents Examined by Carla J. Myers
  • Methylation assay
    Patent number: 10718026
    Abstract: The present invention discloses a method of generating subsets of methylation specific markers from a set, having diagnostic power for various diseases, e.g. cancer of thyroid, breast, colon, or leukemia, in diverse samples; identified subsets of that set, as well as methods for the prognosis and diagnosis of diseases.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: July 21, 2020
    Assignee: AIT Austrian Institute of Technology GMBH
    Inventors: Andreas Weinhausel, Rudolf Pichler, Christa Nohammer
  • Predicting resistance to disease
    Patent number: 10711301
    Abstract: The Invention relates to a method of predicting resistance to infectious pancreatic necrosis in salmon, the method comprising determining the alleles present at a DNA polymorphism in the salmon and predicting whether or not the salmon is resistant to infectious pancreatic necrosis based on the determination of the alleles. The invention also relates to a method of selecting a salmon for use as broodstock, wherein the salmon is selected based on the prediction by the first method that the salmon will have resistance to infectious pancreatic necrosis.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 14, 2020
    Assignee: AquaGen AS
    Inventor: Thomas Moen
  • Predicting resistance to disease
    Patent number: 10711302
    Abstract: The Invention relates to a method of predicting resistance to infectious pancreatic necrosis in salmon, the method comprising determining the alleles present at a DNA polymorphism in the salmon and predicting whether or not the salmon is resistant to infectious pancreatic necrosis based on the determination of the alleles. The invention also relates to a method of selecting a salmon for use as broodstock, wherein the salmon is selected based on the prediction by the first method that the salmon will have resistance to infectious pancreatic necrosis.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 14, 2020
    Assignee: AquaGen AS
    Inventor: Thomas Moen
  • Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
    Patent number: 10704098
    Abstract: Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis disclosed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 7, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Patrick Sleiman
  • Methods for screening solid tumors for mutations
    Patent number: 10689710
    Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 23, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather Sanders, Kevin Qu, James Prentice, Frederic Waldman
  • Clonal haematopoiesis
    Patent number: 10683552
    Abstract: The present invention relates to clonal expansion of somatic cells in subjects, and acquired selective advantage of cell clones during the lifetime of a subject. In particular, the invention relates to methods for predicting the development of cancer based on the observation of specific genetic mutations in somatic cell clones, as well as to methods for treating or preventing cancer in a subject, in which clonal expansion of cells comprising specific modifications is observed.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: June 16, 2020
    Assignees: Presidents and Fellows of Harvard College, The Broad Institute, Inc.
    Inventors: Steven Andrew McCarroll, Giulio Genovese
  • Methods for diagnosing and treating inflammatory bowel disease
    Patent number: 10669587
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: June 2, 2020
    Assignee: GENENTECH, INC.
    Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
  • Immunoglobulin expression levels as biomarker for proteasome inhibitor response
    Patent number: 10662479
    Abstract: Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: May 26, 2020
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Brian Tuch, Jeremiah Degenhardt, Andrea Loehr, Kevin Kwei, Christopher J. Kirk
  • Methods for characterizing cancer
    Patent number: 10633710
    Abstract: A method of identifying gene expression associated with recurrence free survival in a subject with cancer, comprising: a) assaying a sample from a subject diagnosed with cancer for the presence of altered gene expression of one or more genes selected from the group consisting of ADK, AP2B1, AVL9, CANX, DBT, DHRS7, DONSON, FAM190B, FGFR1, FOXN3, FZD5, GGH, GM2A, IGFBP5, ITSN2, LAMC1, LIFR, METTL7A, MT1F, MT1G, MT1P2, MT1X MT2A, NAB1, NCOA1, NCOR1, PAPOLA, PPME1, PPP1R13L, PRKAR2A, RABEP1, RBBP8, SGPL1, SIRT1, SNX2, SREK1, TAF1B, TMED5, and ZMIZ2; and b) identifying an outcome of decreased likelihood of recurrence free survival when altered gene expression relative to the level in a non-cancerous sample is present.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 28, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventor: Joe G. N. Garcia
  • Analysis of methylation status and copy number
    Patent number: 10633706
    Abstract: A method of diagnosing a disease associated with a DNA repeat sequence is disclosed. The method comprises: (a) determining the number of repeats of a DNA sequence in DNA molecules of a sample of the subject; and (b) determining the CpG methylation status of the DNA molecules, wherein the number of repeats of the DNA sequence and the CpG methylation status of the DNA molecules is indicative of the disease.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: April 28, 2020
    Assignees: Ramot at Tel-Aviv University Ltd., Rheinisch-Westfälische Technische Hochschule (RWTH) Aaachen
    Inventors: Yuval Ebenstein, Elmar Weinhold, Assaf Grunwald, Tslil Gabrieli
  • Gene signatures of inflammatory disorders that relate to the liver
    Patent number: 10626471
    Abstract: This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: April 21, 2020
    Assignees: ENTEROME, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
    Inventors: Matthieu Pichaud, Pierre Rimbaud, Stanislav Ehrlich
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10604806
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene KIAA1199 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene KIAA1199 and optionally one or more further marker genes selected from DMBT1, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAMS, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: March 31, 2020
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • Test for predicting the ability of a salmonid to utilise dietary pigment
    Patent number: 10604803
    Abstract: The present invention relates to a method of predicting the ability of a salmonid to utilise dietary pigment, the method comprising determining the alleles present at one or more DNA polymorphism in the abcg 2 gene in the salmonid and predicting the ability of the salmonid to utilise dietary pigment based on the determination of the alleles. Such a method may be used in a method of selecting a salmonid for use as broodstock. The present invention also relates to a method of genome editing in order to create a salmonid with an increased ability to utilise dietary pigment, the method comprising editing the genome of the salmonid in order to introduce one or more red allele of a DNA polymorphism in the abcg2 gene.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: March 31, 2020
    Assignee: AQUAGEN AS
    Inventors: Thomas Moen, Jacob Seilo Torgersen
  • Combinatorial DNA screening
    Patent number: 10597717
    Abstract: The present disclosure relates to methods for detecting unique genetic signatures derived from markers such as, for example, mutations, somatic or germ-line, in nucleic acids obtained from biological samples. The sensitivity of the methods provides for detection of mutations associated with a disease, e.g., cancer mutations, or with inherited disease, e.g., an autosomal recessive disease, in a noninvasive manner at ultra-low proportions of sequences carrying mutations to sequences carrying normal, e.g., non-cancer sequences, or a reference sequence, e.g., a human reference genome.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 24, 2020
    Assignee: MYRIAD WOMEN'S HEALTH, INC.
    Inventors: Jared Robert Maguire, Clement Chu, Imran Saeedul Haque, Eric Andrew Evans, Noah Welker
  • Methylation site regulating expression of mda-9/syntenin
    Patent number: 10597728
    Abstract: Methods of prognosing the outcome of cancer and/or cancer treatment are provided. The methods involve quantitating the level of methylation at a site that regulates expression of the mda-9/Syntenin gene, site cg17197774. High levels of methylation indicate a good prognosis whereas low levels of methylation indicate a poor prognosis and determination of these levels permits risk stratification of patients with cancer.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: March 24, 2020
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Paul B. Fisher, Manny Bacolod
  • Predicting resistance to viral infection
    Patent number: 10577663
    Abstract: The present invention relates to a method of predicting resistance to a viral infection in a subject, the method comprising determining in the subject the variant present at one or more amino acid position in a cadherin protein, and/or the alleles present at one or more DNA polymorphism in the gene for cadherin, and predicting whether or not the subject is resistant to viral infection based on the determination of the variant and/or the alleles.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: March 3, 2020
    Assignee: Aqua Gen AS
    Inventors: Thomas Moen, Jacob Seilo Torgersen, Nina K. Santi
  • Methods for predicting drug responsiveness
    Patent number: 10570457
    Abstract: The present invention provides drug response predictors and biomarkers useful for assessing the responsiveness of a subject to treatment with one or more target drugs of interest, such as 5-fluorouracil (5-FU), irinotecan, and/or oxaliplatin. In particular, the invention provides methods useful in determining whether a subject is sensitive or resistant to a target drug by, e.g., measuring the expression level of one or more biomarkers of sensitivity and/or resistance to the drug in a biological sample obtained from the subject. The invention further features devices and kits for assessing target drug responsiveness in a subject, for example, by determining the expression level of such biomarkers.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: February 25, 2020
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Method for predicting risk of ankylosing spondylitis using DNA copy number variants
    Patent number: 10550432
    Abstract: The present invention relates to a method of predicting the risk of developing ankylosing spondylitis using DNA copy number variation. It was verified that the risk of developing ankylosing spondylitis can be effectively predicted using primers for detecting DNA copy number variation, of the present invention, and the sensitivity and specificity of prediction can be improved by grafting the results of single nucleotide polymorphism (SNP) measurements, and thus more fundamental approaches for preventing and treating ankylosing spondylitis are expected.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 4, 2020
    Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Yeun-Jun Chung, Tae-Hwan Kim, Seung Cheol Shim, Seung-Hyun Jung
  • Method for treating idiopathic pulmonary fibrosis
    Patent number: 10543185
    Abstract: Aspects of the disclosure relate to a method for treating idiopathic pulmonary fibrosis (IPF) in a patient with N-acetylcysteine (NAC) comprising administering NAC to a patient after a sample from the patient has been genotyped and determined to be any one of: a) homozygous or heterozygous for a thymine at the single nucleotide polymorphism rs3750920; b) homozygous or heterozygous for guanine at the single nucleotide polymorphism rs5743894; or c) homozygous or heterozygous for thymine at the single nucleotide polymorphism rs35705950.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: January 28, 2020
    Assignees: The University of Chicago, Cornell University
    Inventors: Imre Noth, Justin Oldham, Fernando Martinez
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10538810
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene KIAA1199 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene KIAA1199 and optionally one or more further marker genes selected from DMBT1, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAMS, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: January 21, 2020
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche